RYBREVANT plus chemotherapy significantly improved treatment discontinuation rates, with 22% of patients remaining on therapy at 18 months compared to only 4% on chemotherapy alone. The median time to treatment discontinuation was 10.4 months for the combination versus 4.5 months for chemotherapy.